← Leaderboards
Kent Rossman
Univ Of North Carolina Chapel Hill
$1,611,025
Attributed
$1,611,025
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $454.1K · FY2018–21$500K$375K$250K$125K$0
'18
'19
'20
'21
Funding mix
By agency
NIH$1,611,025 · 1
By mechanism
R01$1,611,025 · 1
Top collaborators
No co-investigators on record.
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Sharon L Campbell$16,019,656
- John E Sondek$15,232,788
- Bryan L Roth$59,246,636
- Timothy C Elston$15,012,241
- Stephanie Gupton$9,049,928
Others in their field
Other Emerging Leaders on “Advanced Malignant Neoplasm”
- Leonard Freedman · Leidos Biomedical Research, Inc.$354,493,986
- Leonard Freedmand · Leidos Biomedical Research, Inc.$79,963,641
- Lynn Briscoe · Leidos Biomedical Research, Inc.$47,097,978
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
- Tareq Al Baghdadi · Saint Joseph Mercy Health System$19,225,531
Research focus
Advanced Malignant NeoplasmAffinityAmino Acid SubstitutionAnticancer ResearchBaseBindingBinding SitesBiochemicalBiological SystemsBraf GeneBypassCancer TherapyCancer TypeCell ProliferationCellsCessation Of LifeChemotherapyColorectalColorectal CancerColorectal NeoplasmsCrystallizationCysteineDesignAccounting
Grant awards (4)
A HTS Approach to Discover Guanine Nucleotide-Competitive Inhibitors of Oncogenic KRAS$389,545
R01 · FY2021 · CA · contact PI
A HTS Approach to Discover Guanine Nucleotide-Competitive Inhibitors of Oncogenic KRAS$389,545
R01 · FY2020 · CA · contact PI
A HTS Approach to Discover Guanine Nucleotide-Competitive Inhibitors of Oncogenic KRAS$377,858
R01 · FY2019 · CA · contact PI
A HTS Approach to Discover Guanine Nucleotide-Competitive Inhibitors of Oncogenic KRAS$454,077
R01 · FY2018 · CA · contact PI